Growth suppression of human laryngeal squamous cell carcinoma by adenoviral-mediated interleukin-12

Journal of International Medical Research

Volumn 38, Issue 3, 2010, Pages 994-1004

  Tian, L ^a   Chen, X ^b   Sun, Y ^a   Liu, M ^a   Zhu, D ^a   Ren, J ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Adenoviral mediated interleukin 12; Apoptosis; Gene therapy; Interleukin 12; Laryngeal squamous cell carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; INTERLEUKIN 12; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EPITHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEP 2 CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARYNX CARCINOMA; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; XENOTRANSPLANTATION; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; HEPG2 CELL LINE; LARYNGEAL NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES; ULTRASTRUCTURE; VIROLOGY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; GENETIC THERAPY; GENETIC VECTORS; HEP G2 CELLS; HUMANS; INTERLEUKIN-12; LARYNGEAL NEOPLASMS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; TETRAZOLIUM SALTS; THIAZOLES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954804717     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800326     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, et al: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
2. Gabrilovich D, Pisarev V: Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 2003; 4: 525-536.
3. Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
4. Kobayashi M, Fitz L, Ryan M, et al: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 17: 827-845.
5. Gubler U, Chua AO, Schoenhaut DS, et al: Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991; 88: 4143-4147.
6. Wolf SF, Temple PA, Kobayashi M, et al: Cloning for cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biological effects on T and natural killer cells. J Immunol 1991; 146: 3074-3081.
7. Puisieux I, Odin L, Poujol D, et al: Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum Gene Ther 1998; 9: 2481-2492.
8. Motzer RJ, Rakhit A, Schwartz LH, et al: Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998; 4: 1183-1191.
9. Voest EE, Kenyon BM, O'Reilly MS, et al: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586.
10. Spector JG, Sessions DG, Haughey BH, et al: Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope 2001; 111: 1079-1087.
11. Moon C, Oh Y, Roth JA: Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res 2003; 9: 5055-5067.
12. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
13. Brunda MJ: Role of IL12 as an anti-tumour agent: current status and future directions. Res Immunol 1995; 146: 622-628.
14. Adappa ND, Sung CK, Choi B, et al: The administration of IL-12/GM-CSF and Ig-4-lBB ligand markedly decreases murine floor of mouth squamous cell cancer. Otolaryngol Head Neck Surg 2008; 139: 442-448.
15. Chuang TF, Lee SC, Liao KW, et al: Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. Int J Cancer 2009; 125: 698-707.
16. Tros De Ilarduya C, Bunuales M, Qian C, et al: Antitumoral activity of transferrin-lipoplexes carrying the IL-12 gene in the treatment of colon cancer. J Drug Target 2006; 14: 527-535.
17. Ahn WS, Bae SM, Kim TY, et al: A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther 2003; 14: 1389-1399.
18. Lafleur EA, Jia SF, Worth LL, et al: Interleukin (IL)-l2 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res 2001; 61: 4066-4071.
19. Harada N, Shimada M, Okano S, et al: IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol 2004; 173: 6635-6644.
20. Sgadari C, Angiolillo AL, Tosato G: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877-3882.
21. Yao L, Sgadari C, Furuke K, et al: Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999; 93: 1612-1621.
22. Dias S, Boyd R, Balkwill F: IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998; 78: 361-365.
23. Duda DG, Sunamura M, Lozonschi L, et al: Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000; 60: 1111-1116.
24. Xie M, Sun Y, Li Y: Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope 2004; 114: 2243-2248.
25. Sun Y, Liu M, Yang B, et al: Inhibition of laryngeal cancer cell invasion and growth with lentiviral-vector delivered short hairpin RNA targeting human MMP-9 gene. Cancer Invest 2008; 26: 984-989.
26. Griffith TS, Ferguson TA: The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997; 18: 240-244.
27. Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, et al: P-Catenin, NF-kB and FAS protein expression are independent events in head and neck cancer: study of their association with clinical parameters. Cancer Lett 2005; 230: 141-148.
28. Gastman BR, Atarshi Y, Reichert TE, et al: Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356-5364.
29. Zhou Z, Lafleur EA, Koshkina NV, et al: Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol Cancer Res 2005; 3: 685-691.
30. van Herpen CM, van der Voort R, van der Laak JA, et al: Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer 2008; 123: 2354-2361.